Figure 2.

Progression-free interval (PFI) and overall survival (OS) of melanoma patients depending on the RPL23AP53 expression levels in: group of all patients (A), patients with BRAF mutation (B) and patients with wild type of BRAF gene (C); results presented for 3 years of observation; low (red solid lines) and high (black solid lines) subgroups represent patients with 1st and 4th quartile of gene expression level for A panel and median expression level for panels B and C; p^a — Log-rank (Mantel-Cox) test; p^b — Gehan-Breslow-Wilcoxon test; 95% CI — 95% of confidence interval marked as dashed red and black lines; p < 0.05 considered as significant